Mayank

The future of pharma AI may not live in the cloud. It may live inside the company firewall. Possibly even… under someone’s desk. For the last decade, “cloud-first” became the default enterprise strategy. AWS, Azure, and GCP made it easy to scale compute without owning hardware. For many workloads, that model works perfectly. But pharma is different. The data used in commercialization and strategy often includes: • Pre-approval clinical insights • Pricing and access strategies • Competitive intelligence • Internal forecasts and market models In other words: material non-public information. And once AI enters the picture, a simple question emerges: Where should the models actually run? A growing answer is: locally. We're starting to see the rise of AI appliances — purpose-built machines running models on-premise, often in secure or even air-gapped environments. If this sounds familiar, it should. In the early 2000s we saw blade servers emerge: small, specialized machines clustered together for parallel workloads. AI appliances follow the same pattern: • purpose-built hardware • clustered processing • specialized workloads But with modern advances like unified memory architectures, relatively small systems can now run models that recently required massive GPU clusters. The implications for biopharma could be significant. Imagine an emerging biotech preparing for its first launch. Instead of spending $3–5M and 6–12 months assembling launch plans across consulting teams… An internal AI system could generate coordinated first drafts across: • market access • medical affairs • brand strategy • field operations in hours. Humans still provide judgment. AI handles the synthesis. The result: • faster strategic iteration • lower costs • tighter compliance control Computing has always moved like a pendulum: Mainframes → PCs → Blade Servers → Cloud. AI may be pushing the pendulum again. Question for you: Where do you think enterprise AI will run in regulated industries over the next 5 years — cloud, hybrid, or primarily on-prem?

Two signals this week: Eric Topol: AI will expose unmet patient need Center for Biologics Evaluation and Research: rare disease approvals accelerating Same reality: Patients were always there What’s changing: •Faster diagnosis (AI) •Faster approvals What’s not: •Commercial readiness The bottleneck isn’t science anymore. It’s execution. Access > approval. AI will surface patients. But only companies with commercial infrastructure ready pre-approval will reach them. That gap is about to widen fast. #raredisease #AI #biotech

FDA Plausible Mechanism Framework The FDA just told us something important about the future of drug development. For rare and ultra-rare diseases — where running a randomized controlled trial is impossible — they’ve now outlined a path to approval based on a “plausible mechanism framework.” No RCT required. If the biology is understood, the mechanism is causal, and the effect is measurable: that can be enough. Commissioner Makary put it plainly: “No randomized trial will be required because it’s simply infeasible.” This is significant. But not for the reason most people think. The headline story is regulatory. A new pathway. A faster route to approval. A win for rare disease patients. All true. The commercial story is what nobody’s talking about. When you compress or eliminate the RCT, you also compress the evidence base that commercial teams have traditionally leaned on. No Phase 3 data package. No large trial population to characterize. No comparative arms to hang a value dossier on. You’re launching a therapy built on mechanistic evidence — and asking payers, physicians, and patients to trust it. That changes everything about how you build a commercial model. Three implications I’m thinking through: 1. Value dossiers have to be rebuilt from the ground up. AMCP-format submissions are designed around RCT data. When the evidence package is a plausible mechanism + early-phase safety data, the value story becomes: disease biology, genetic causal chain, and a coherent theory of durability. Payer teams that don’t know how to write that story are going to struggle. 2. Outcomes-based contracts become mandatory, not optional. Without long-term comparative data, the only way to bridge the payer trust gap is to take on outcome risk yourself. This is actually an opportunity — but only if you’ve designed your commercial model to support real-world data collection from Day 1. 3. The regulatory-commercial boundary just got blurrier. Under the traditional model, commercial teams waited for approval, then built. Under plausible mechanism approvals, commercial strategy has to inform what evidence gets generated post-approval. That’s a fundamental change to how launch teams are structured. The rare disease companies that will win under this framework aren’t the ones who treat approval as the finish line. They’re the ones who treat Day 1 post-approval as the beginning of their evidence generation strategy — with commercial infrastructure built around collecting it. The FDA just opened a door. The question is whether commercial teams are ready to walk through it. Mayank Misra is Managing Partner at Charles River Healthcare Partners. He advises biopharma commercial teams on launch strategy, market access, and AI-enabled commercialization. Author: The Biotech Launch Algorithm: How Multi-Agent AI Is Rewriting Drug Commercialization a.co/d/0e4OlvlC Reference: Source: FDA Draft Guidance, Feb 23 2026 + Arnold & Porter Advisory arnoldporter.com/en/perspect… Tags: #RareDisease #FDAPolicy #BiopharmaCom #DrugLaunch #MarketAccess #PrecisionMedicine #GeneTherapy #CommercialStrategy

Longform here: charlesriverhcp.substack.com…

After 25 years and more than 20 drug launches, I've seen the same failure happen repeatedly. A drug passes a critical trial. The team celebrates. Then the work begins on the launch plan to coordinate more than 20 teams and sub-teams with overlapping timelines and different interpretations of the base case assumptions. The response to "Are we ready to launch?” is almost never yes. Not because people aren't talented or the team isn't organized. Nor because the strategy is wrong.  It’s because building a complete commercial launch plan — across brand, market access, medical affairs, regulatory, payer, and field — takes 18 months of coordinated work. And 6 months before approval is not the time to start. Each month of ramp-up delay to the planned go-to-market model costs a blockbuster program $40–80 million in forgone revenue. We've accepted this as a cost of doing business. I think that's wrong. In October 2025, I started building something to fix it. Today, that work is a book. The Biotech Launch Algorithm: How Multi-Agent AI Is Rewriting Drug Commercialization is out now— available on Kindle, paperback, and hardcover. a.co/d/0cqCnKy6 It's not an AI hype book. It's a practitioner's account of what actually happens when you deploy 13 specialized AI agents to do the work of a full commercial launch team — in hours, not months. Part I: The structural failure in traditional launch preparation.  Part II: the architecture — 13 agents, how they coordinate, what they know that the others don't.  Part III: a complete real-world launch plan for atacicept in IgA Nephropathy. Seven full deliverables. $1.20 in comput. Honest about the limits.  Part IV: What comes next for the industry? If you lead commercial strategy, run a biotech, advise on launch readiness, or invest in companies that are about to launch — this is for you. The copilot model isn't coming. It's here. Link in comments. #BiotechLaunch #PharmaAI #DrugCommercialization #AIinPharma #Biotech #CommercialStrategy #LaunchExcellence #MultiAgentAI

The FDA Just Compressed the Launch Window. Is Your Commercial Team Ready? One-trial approvals aren’t just a regulatory shift — they’re a forcing function for AI-enabled launch execution. The Rule Change Nobody in Commercial Is Talking About Last week, the FDA signaled it will now accept a single well-controlled clinical trial as the basis for drug approval. The oncology and rare disease world responded — mostly with celebration. Faster approvals. Shorter timelines. Less time between promising data and patients. All true. But here’s what I haven’t seen anyone say: this change doesn’t just compress the clinical timeline. It compresses the commercial one. And commercial teams are not ready for it. What Two Trials Gave You (That You’re About To Lose) Under the traditional two-trial standard, the gap between first pivotal data readout and approval gave commercial teams something invaluable: time to be wrong and fix it. You ran your market research. You built your payer strategy. You mapped your KOLs. You launched your disease awareness campaign. And then, before the PDUFA date arrived, you had 12–18 months of additional data — and additional market intel — to pressure-test your assumptions. The second trial wasn’t just a scientific confirmation. It was a commercial runway. One trial collapses that runway. You now have one shot at first-in-human data → regulatory submission → approval → launch readiness. The margin for commercial unpreparedness just got thinner. The Inconvenient Secret of Drug Launches I’ve spent 25 years on drug launches — twenty-plus products. Three co-promote alliances. Blockbusters and quiet failures. The inconvenient secret no one publishes in a journal: most drugs that underperform at launch don’t fail for clinical reasons. They fail for commercial ones. Incomplete payer coverage. Underdeveloped market access strategy. KOL networks were built too late. Patient identification models that miss the actual diagnosed population. Messaging that doesn’t land with the prescribers who matter. These aren’t exotic failures. They happen on nearly every launch, to some degree. The difference between a good launch and a great one — measured in hundreds of millions of dollars — usually comes down to how early the commercial team got serious, and how fast they could iterate. The two-trial model gave teams a second chance. The one-trial model doesn’t. Why This Is AI’s Moment in Commercial This is the context of why we need a Biotech Commercialization CoPilot — an algorithmic, multi-agent AI system purpose-built for biopharma launch. Not because AI is fashionable. Because the math no longer works any other way. A modern precision oncology launch demands simultaneous expertise across: regulatory strategy, payer architecture, patient identification, HCP segmentation, medical affairs coordination, competitive intelligence, field deployment modeling, and executive reporting. The idea that a human commercial team — even a well-resourced one — can run all of those workstreams in parallel, with perfect cross-functional information symmetry, at the speed a one-trial approval demands, is increasingly a fantasy. Multi-agent AI doesn’t replace the experienced launch team. It multiplies them. In a CoPilot-enabled commercial workflow, AI agents run concurrently: market access, competitive intel, KOL strategy, patient journey mapping, messaging architecture, field sizing, payer engagement, and regulatory alignment. They share a common data layer. They surface conflicts. They flag gaps. They produce a launch plan draft in days — not months. Human judgment still governs every critical decision. But the preparation for those decisions — the analysis, the scenario modeling, the first draft of every strategy — gets done at machine speed. For a team staring down a single PDUFA date with no second pivotal runway, that’s not a competitive advantage. It’s a survival requirement. What the FDA’s Move Really Signals The one-trial shift is being framed as a patient-access win — and it is. Faster approvals mean patients get treatments sooner. But the deeper signal is competitive. The FDA is accelerating the pace of drug approvals. The commercial infrastructure to support those drugs hasn’t accelerated at the same rate. That gap — between faster science and slower commercial readiness — is where launches go to die. Whoever builds the best single-trial commercial readiness model wins. That’s the argument I’ve been making for years in conference rooms, and now in the forthcoming book The Biotech Launch Algorithm. The FDA just put it on the front page. The Implication for Rare Disease and Precision Oncology This shift hits hardest in the spaces where single-trial approvals are most likely: rare disease and biomarker-driven oncology. They don’t have the infrastructure of a large Pharma. They can’t staff 50-person launch teams. And now they’re racing toward approval on a single data package, needing to be commercially ready at the moment the label prints. AI-enabled launch acceleration isn’t a luxury product for these teams. It’s the only way to compete. What To Do About It Start your commercial infrastructure earlier than you think you need to. If your PDUFA date is 18 months out, your payer strategy, patient identification model, and KOL engagement plan should already be in draft. Build AI into your workflow, not onto it. AI tools bolted onto a traditional commercial process add cost without adding speed. Treat launch readiness as a continuous score, not a checklist. One of the core design principles of CoPilot is that launch readiness should be a live metric — updated weekly, visible to the ELT. The FDA’s one-trial shift is an argument your board needs to hear. This is the moment to make the case for accelerated commercial investment. Final Thought The question isn’t whether AI belongs in a commercial launch strategy. That debate is over. The question is how fast you can deploy it before your window closes. Author: Mayank Misra : 2026-03-02 Mayank Misra is the author of The Biotech Launch Algorithm: How Multi-Agent AI Is Rewriting Drug Commercialization (forthcoming, KDP, March 2026). Follow on LinkedIn: linkedin.com/in/mayankmisra | Substack: @charlesriverhcp #BiopharmaCom #DrugLaunch #AIinPharma #CommercialStrategy #RareDisease #Oncology #FDAPolicy #BiotechLaunch

#CRISPR Broke the Pharma Playbook Gilead just paid $7.8 billion for Arcellx — a 79% premium, before the drug even had FDA approval. That's not a science bet. That's a commercial execution bet. The question isn't whether anito-cel works. Gilead knows the data — they were already a development partner. The question is whether anyone can actually commercialize a next-generation cell therapy faster and better than the first generation managed. Because the first generation had serious problems. Not with the science. With the playbook. **Four rules gene therapy broke:** **1. "You sell to physicians."** Gene therapy: the physician refers the patient to one of maybe 50 authorized treatment centers in the country. The center needs certified staff, protocols, and apheresis infrastructure. The prescribing conversation is step one of a five-step process. **2. "Payers manage risk through formulary."** Gene therapy: you're asking a payer to write a $3 million check, once, for a therapy whose long-term durability is still being established. Outcomes-based contracts sound reasonable until you try to define "outcomes" over a 5-year horizon. **3. "Manufacturing is someone else's problem."** Autologous cell therapy: the manufacturing IS the patient. Vein-to-vein time runs 34–65 days. Every batch failure is a clinical and commercial event simultaneously. **4. "Launch fast, optimize later."** Gene therapy patient populations are often in the thousands, not millions. Every patient you miss in year one is a meaningful percentage of your addressable market. There is no "optimize later." Kymriah taught us what happens when you try to adapt the old playbook. Carvykti at $1.9B shows what it looks like when you build a better one. Casgevy is writing the next chapter right now, in real time. The teams building purpose-designed commercial models for gene editing — not adapted ones — will set the standard. The Biotech commercialization playbook is broken. Watch this space :) --- #CRISPR #GeneTherapy #CARTcelltherapy #PharmaStrategy #Biopharma #Commercialization #LaunchExcellence #MarketAccess

The Patient Is Becoming the Customer Your launch team still thinks doctors write prescriptions. They do. But patients are now Googling your drug before the doctor mentions it — and forming opinions before they walk into that appointment. The launch playbook built in the 1990s was designed for a world where the physician was the customer. You detailed to HCPs. You waited for prescriptions. You measured reach and frequency. That world is mostly over. Here's what changed: **Telehealth rewired the access model.** A telehealth-native launch strategy looks completely different from a field-force-first strategy. Different KPIs, different call plans, different definitions of reach. The patient's geography no longer determines their access to a prescriber. Most launch plans haven't caught up. **Direct-to-patient isn't a logistics upgrade.** When a specialty pharmacy ships to the patient's door with built-in adherence check-ins and real-time data capture, that's not a fulfillment improvement. It's a commercial strategy shift — one that generates real-world evidence your traditional distribution channel never could. **Patients arrive with opinions.** They've researched the disease. They've compared treatments. They've read other patients' stories online. The physician conversation is no longer a first introduction — it's often a confirmation. The brands that meet patients with honest, useful, compliant content earn trust that shapes that conversation downstream. And then there's gene therapy — where the "patient as customer" thesis hits its most extreme stress test. A one-time $3 million therapy requires a level of patient engagement that no traditional commercial model was designed to support. If your launch plan doesn't have a direct-to-patient channel strategy, a patient services model integrated into your commercial plan, and a compliance framework for digital engagement — you're planning for 2015. The patient isn't becoming the customer. They already are. --- #PharmaStrategy #DrugLaunch #Biopharma #Commercialization #PatientAccess #HealthcareInnovation #LaunchExcellence

Looking forward to the Endpoints Webinar and sharing my thoughts on AI in life sciences: Reimagining teams, technology, and partnerships for the future. webinars.endpoints.news/ai-i…